The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Angela DeMichele
Consulting or Advisory Role - Pfizer (I)
Research Funding - Calithera Biosciences (Inst); Genentech (Inst); Inivata/NeoGenomics (Inst); Novartis (Inst); Pfizer (Inst)
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck
 
Charles Perou
Stock and Other Ownership Interests - Bioclassifier; GeneCentric; Reveal Genomics
Consulting or Advisory Role - GeneCentric
Patents, Royalties, Other Intellectual Property - Bioclassifier; Bioclassifier (Inst); Gene Expression Profiles to Predict Breast Cancer Outcomes; U.S. Patent No. 12,995,459; Gene Expression Profiles to Predict Breast Cancer Outcomes; U.S. Patent No. 12,995,459 (Inst)
 
Otto Metzger
Honoraria - AstraZeneca; Genzyme; Merck; SCIBR Foundation
Consulting or Advisory Role - Alliance for Clinical Trials in Oncology; Grupo Oncoclinicas; Resilience Care
Research Funding - Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Grupo Oncoclinicas
 
Heather Anne Parsons
Consulting or Advisory Role - Caris Life Sciences; Illumina
Research Funding - Puma Biotechnology (Inst)
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Athenex; Bristol-Myers Squibb; Genomic Health; Halozyme; Merck; Pfizer; Pfizer; Polyphor; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Medimmune (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
 
Gabrielle Betty Rocque
Consulting or Advisory Role - Flatiron Health; Gilead Sciences; Pfizer
Research Funding - Carevive Systems; Genentech; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences
 
Wenliang Yao
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Shawn W. Sun
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Simonetta Mocci
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
 
Lisa A. Carey
Research Funding - AstraZeneca (Inst); NanoString Technologies (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly; Novartis (Inst); SeaGen